



Suggested Formula	Dexamethasone Sodium Phosphate 26.4 mg/mL Intravenous Injection (Solution, 100 mL)	FIN	F 004 590v2
-------------------	--	-----	-------------

Note: Dexamethasone Sodium Phosphate 26.4 mg/mL is equivalent to Dexamethasone Phosphate 24 mg/mL.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dexamethasone Sodium Phosphate, USP	2.640	g				
Sodium Bisulfite, USP	0.10	g				
Sodium Citrate, USP	1.10	g				
Edetate Disodium, USP	0.05	g				
Benzyl Alcohol, NF	1.0	mL				
Sterile Water For Injection, USP	80.0	mL				
Sterile Water For Injection, USP	q.s. to 100.0	mL				
Sodium Hydroxide 10% solution	As needed					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible): Dexamethasone Sodium Phosphate

Hygroscopic (protect from moisture whenever possible): Dexamethasone Sodium Phosphate

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Dexamethasone Sodium Phosphate 26.4 mg/mL Intravenous Injection (Solution, 100 mL)	FIN	F 004 590v2
-------------------	--	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Dexamethasone Sodium Phosphate, USP §	2.640	g			
Sodium Bisulfite, USP	0.10	g			
Sodium Citrate, USP	1.10	g			
Edetate Disodium, USP	0.05	g			
Benzyl Alcohol, NF	1.0	mL			
Sterile Water For Injection, USP §	80.0	mL			
Sterile Water For Injection, USP §	q.s. to 100.0	mL			
Sodium Hydroxide 10% solution §	As needed				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

<u>Preparatory Instruction</u> IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique	
1.	<p><u>Equipment sterilization:</u></p> <p>Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.</p>
2.	<p><u>Powder-liquid preparation:</u></p> <p>A. In the given order, sequentially add the following ingredients to the Sterile Water For Injection (80.0 mL <i>plus</i> processing error adjustments):</p> <ul style="list-style-type: none"> -Dexamethasone Sodium Phosphate -Sodium Bisulfite -Sodium Citrate -Edetate Disodium -Benzyl Alcohol <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p> <p><u>Note:</u> Add the next ingredient, once the previous one has been completely added and dissolved.</p>



Suggested Formula	Dexamethasone Sodium Phosphate 26.4 mg/mL Intravenous Injection (Solution, 100 mL)	FIN	F 004 590v2
-------------------	--	-----	-------------

3.	<p><u>pH testing:</u></p> <p>A. Draw an appropriate amount of the mixture (Step 2A).</p> <p>B. Test the pH of the sample. It should lie between 7.0 and 7.5.</p> <p>C. <u>If the pH < 7.0, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% solution.3. Re-test the pH.4. Continue to add the Sodium Hydroxide 10% solution until the pH of 7.0 to 7.5 is obtained. <p>IMPORTANT: Do not allow the pH to rise above 7.5.</p>
4.	<p><u>Filling to volume:</u></p> <p>A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specification:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>
5.	<p><u>Filtering and transferring:</u></p> <p>Aseptically filter the solution through a 0.22-μm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>
6.	<p><u>Filter integrity test:</u></p> <p>Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.</p>
7.	<p><u>Sterility testing:</u></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p>



Suggested Formula	Dexamethasone Sodium Phosphate 26.4 mg/mL Intravenous Injection (Solution, 100 mL)	FIN	F 004 590v2
-------------------	--	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated as per USP 797 BUD based on a successful sterility and endotoxin test result.	Packaging Requirements	Sterile, light-resistant, unit dose glass injection vials.
Auxiliary Labels	1 Use as directed. Do not exceed prescribed dose.	6	Discard in the presence of particulate matter.
	2 Keep out of reach of children.	7	Discard container after use.
	3 Keep refrigerated. Do not freeze.	8	Protect from light.
	4 Equilibrate to room temperature before use.	9	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	5 Do not use if product changes color.	10	Hypertonic solution, inject slowly.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. Note: Benzyl Alcohol is not suitable to use in neonates.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		

REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Dexamethasone (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #2943.
3.	Dexamethasone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3rd Edition</i> . American Pharmaceutical Association; 2005: 135.
4.	Dexamethasone (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2087.
5.	USP <797>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 318.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.